Boston Scientific (NYSE:BSX) today posted 1st-quarter sales that topped expectations on Wall Street, but share prices slid anyway in pre-market trading as investors reacted to a 1¢ miss on earnings.
The Marlborough, Mass.-based company reported profits of $290 million, or 21¢ per share, on sales of $2.16 billion for the 3 months ended March 31, for a bottom-line gain of 43.6% on sales growth of 10.0% compared with Q1 2016. Adjusted to exclude 1-time items, earnings per share came in a penny below The Street at 29¢. Analysts were looking for sales of $2.08 billion.
